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Summary 26 
Migration is a key driver of tuberculosis (TB) in many low incidence settings, with the majority of TB cases 27 
attributed to reactivation of latent TB (LTBI) acquired overseas. A greater understanding of LTBI risk in 28 
heterogeneous migrant populations would aid health planning. We aimed to estimate the LTBI prevalence 29 
and distribution among local and overseas-born Australians. 30 
Annual risks of tuberculosis infection estimates were applied to population cohorts (by country of birth, year 31 
of arrival and age) in Australian census data in 2006, 2011 and 2016. 32 
Both the absolute number and proportion of Australian residents with LTBI increased – from 4.6% (IQR 33 
[interquartile range] 4.2-5.2%) in 2006 to 5.1% (IQR 4.7%-5.5%) in 2016 – due to the increasing proportion of 34 
the population born overseas (23.8% in 2006 to 28.3% in 2016). Of all residents estimated to have LTBI in 35 
2016; 93.2% were overseas born, 21.6% were <35 years of age and 34.4% had migrated to Australia since 36 
2007. 37 
The overall prevalence of LTBI in Australia is low. Some residents, particularly migrants from high incidence 38 
settings, may have considerably higher risk of LTBI, and these findings allow for tailored public health 39 
interventions to reduce the risk and impact of future TB disease.  40 
KEY WORDS: migration, epidemiologic methods, mathematical modelling 41 
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Introduction  50 
In many low-incidence settings, most TB cases now occur among residents born in high-incidence countries 51 
and are attributed to reactivation of latent TB (LTBI) acquired overseas.1 LTBI is asymptomatic and not 52 
infectious, but those with LTBI can be treated to reduce their future risk of reactivation TB,2 and several low-53 
incidence countries are now considering, or have implemented, screening and treatment for LTBI among 54 
high-risk recent immigrants.3 It is essential that any strategy is well targetted to those at highest risk of active 55 
TB to ensure a favourable risk/benefit ratio for both society and individuals.4 5 However, migrant populations 56 
can be very heterogeneous with regards to source country, age and time since migration, and most LTBI 57 
prevalence studies in migrant populations are limited to opportunistically selected groups with identifiable 58 
risk factors and demographic profiles that are unlikely to be generalisable to the entire migrant cohorts.6  59 
In 2016, Houben and Dodd estimated the prevalence of global LTBI by estimating trends in annual risk of 60 
infection (ARTI) for 168 countries from 1934 to 2014.7 In Australia, as in many low-incidence settings, 61 
immigration is a key driver of the burden of LTBI and rich data exist on immigration by country of origin, age 62 
and year. Therefore, the potential exists to combine estimated TB infection rates with domestic census data 63 
to quantify the LTBI burden and understand the effects of immigration.  64 
We aimed to estimate the prevalence of LTBI in Australia, to describe its evolution over time and identify 65 
populations at greatest risk of infection. This is an important first step in identifying those populations that 66 
are at the highest risk of TB reactivation, and will inform future effective public health interventions towards 67 
TB elimination. 68 
 69 
Methods 70 
Australian census data 71 
Australian population data from the 2006, 2011 and 2016 censuses were exported from the Australian 72 
Bureau of Statistics (ABS) Table Builder8 by country of birth, age, year of arrival, State/Territory of residence 73 
and residence within State/Territory’s capital city.  74 
Residents categorised as “not stated”, “inadequately described”, “overseas visitor” or “at sea” in the census 75 
country of birth or year of arrival categories were excluded from analysis.9  76 
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Annual risk of infection 77 
The methods used by Houben and Dodd 2016 to construct trends in annual risk of infection (ARTI) for 168 78 
countries from 1934 to 2014 have been described in detail previously.7 Briefly, for each country and for each 79 
year, 200 simulated ARTI trajectories were estimated using data from tuberculin skin test (TST) surveys, with 80 
sample size and mean age used to quantify uncertainty. Where TST surveys were unavailable, estimates of  81 
ARTI were obtained using a revised Styblo ratio that accounts for uncertainty.10 The Styblo ratio relates the 82 
annual risk of infection and prevalence of smear-positive tuberculosis.11 12 The prevalence of smear-positive 83 
TB was estimated using WHO Global TB Programme prevalence estimates (1990–2014)13 and incorporating 84 
WHO assumptions regarding case detection rates and disease duration by HIV-status, as well as assumptions 85 
regarding the fraction of smear-positive disease by HIV status14 and age-group.15  86 
To increase precision for the six most common countries of birth in Australia (Australia, the United Kingdom, 87 
China, Vietnam, India and the Philippines), we simulated 5000 ARTI trajectories. To reflect characteristics 88 
relevant to transmission in Australia, the proportion of TB cases that were smear-positive was set to 21.5% 89 
based on the Australian average proportion from 2008 to 2013.1 16-18  The ARTI estimate for 2014 was also 90 
applied to the years 2015 and 2016.  91 
The risk of infection for each population cohort (by country of birth, age and year of arrival if overseas-born) 92 
in each census dataset was calculated by summing the relevant hazards (FOI=force of infection) for each year 93 
of residency in Australia and birth country (for overseas-born residents). To account for variation in birth 94 
dates and dates of migration across years (which were unknown), the hazards in birth years were halved, 95 
and in years of migration half the hazard for each of the birth country and Australia was used. This assumes 96 
that the average time of birth or migration of the cohort was the mid-point of the year of birth or migration. 97 
Hazards in census years were apportioned based on the census date. The total risk of infection (R) for each 98 
population group was then calculated as one minus the exponential of the cumulative FOIs experienced: 99 
𝑅 = 1 − 𝑒∑ −(𝐴𝑙𝑙 𝐹𝑂𝐼𝑠) where FOI=force of infection  100 
A full mathematical description of this method appears in the Appendices.  101 
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 106 
RESULTS 107 
LTBI in Australia 108 
The number of Australians estimated to have LTBI increased over time from approximately 838,000 (IQR 109 
[interquartile range] 764,000-950,000) in 2006 to 1,084,000 (IQR 1,017,000-1,172,000) in 2016, with the 110 
percentage of Australians estimated to have LTBI increasing from 4.6% (IQR 4.2%-5.2%) in 2006 to 5.1% (IQR 111 
4.7%-5.5%) in 2016 (Figure 1). Our results are estimates based on a Bayesian approach, and so computing P-112 
values for comparisons between years was not appropriate, but the uncertainty intervals suggest no strong 113 
evidence of a trend. 114 
Considering the Australian-born and overseas-born groups separately, the estimated LTBI percentages in the 115 
Australian-born residents were comparable in 2006 and 2016 (0.4% [IQR 0.3-0.9%] and 0.4% [IQR 0.3-0.7%]) 116 
and the percentage of overseas-born residents infected also changed little from 18.0% (IQR 16.7-19.6%) to 117 
17.1% (IQR 16.2-18.1%). The reason why the proportions in the Australian-born and overseas-born 118 
subgroups changed little over time while there was a simultaneous increase in the proportion of all 119 
Australians estimated to have LTBI was because of the increasing proportion of the Australian population 120 
who were born overseas during the study years (23.8% in 2006 to 28.3% in 2016). The number of overseas-121 
born residents estimated to have LTBI increased from 756,000 (IQR 699,000-822,000) in 2006 to 998,000 122 
(IQR 943,000-1,058,000) in 2016. 123 
With declining ARTI estimates in many countries worldwide, the percentage estimated to have LTBI 124 
increased with age in both Australian-born and overseas-born populations (Figure 2). Due to the age 125 
distribution of the populations (not shown) the largest number estimated to have LTBI were in the 35-64 126 
year age-groups (Figure 2).  127 
Among overseas-born residents, the number of persons with LTBI increased from 2006 to 2016 in all age 128 
groups, with the largest absolute increase in the 35-64 year and 15-34 year age groups, and percentage 129 
increases of 37.7%, 69.4%, 25.4% and 26.6% in the 0-14, 15-34, 35-64 and 65+ age groups respectively 130 
(Figure 2). The proportion of overseas-born residents estimated to have LTBI appeared to decrease 131 
marginally over time in all age-groups, except in the 35-64 year group, in which it changed little from 19.5% 132 
(IQR 17.9%-21.1%) in 2006 to 20.1% (IQR 18.7%-21.3%) in 2016 (Figure 2).  133 
The average age of residents with LTBI appeared to decrease slightly from 51.9 years in 2006 to 50.7 years in 134 
2016; increasing in the Australian-born population (50.5 years in 2006 to 52.4 years in 2016) and decreasing 135 
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in the overseas-born (52.0 years in 2006 to 50.6 years in 2016). The percentage of residents with LTBI under 136 
the age of 35 years increased from 17.4% in 2006 to 21.6% in 2016.  137 
Overseas-born residents 138 
In 2016, over 6.1 million Australian residents were born overseas in over 190 countries, constituting 28.3% of 139 
the Australian population. The increasing numbers of Australians born in high burden countries19 over time is 140 
illustrated in Figure 3. Australian residents born in India, China, the Philippines and Vietnam made up the 141 
greatest number estimated to have LTBI in 2016; with the prevalence varying by age (Table 1 and Figure 4). 142 
Overseas-born residents arriving 2007-2016 143 
An estimated 15.4% of migrants arriving from 2007 until the census in 2016 had LTBI on arrival, with this 144 
group contributing 34.4% of all LTBI in Australia in 2016 and new migrants aged under 35 years contributing 145 
16.3%.  146 
Spatial distribution  147 
The majority of persons with LTBI resided in major urban centres, particularly Greater Sydney and Greater 148 
Melbourne (Figure S1). LTBI prevalence increased in all regions from 2006 to 2016, most notably in the 149 
Northern Territory (1.7% in 2006 to 3.3% in 2016), Greater Perth (3.8 to 4.9%) and the Australian Capital 150 
Territory (2.8 to 3.9%). It is also possible to identify where those at greatest risk of TB infection live in urban 151 
areas, if census data provides this level of spatial detail (Figure S1).  152 
Missing data 153 
The percentage missing country of birth and/or year of arrival information in the 2006, 2011 and 2016 154 
census data was 8.0%, 6.7% and 9.15% respectively. These census respondents were categorised as “not 155 
stated” and for a significant percentage (~70-80% depending on the year) the answers to most other census 156 
questions were similarly “not stated”, suggesting they had been imputed by the ABS to account for non-157 
responding dwellings.9 20 21 The ABS post-enumeration survey data in the census years estimated the majority 158 
of non-responders to be Australian-born (e.g. 84.8% in 2016, which was calculated using the Tablebuilder 159 
census count and published net undercount rate of 8.1%).9 20 21 and countries of birth of other non-160 
responders were similarly distributed to census respondents in 2016.  161 
DISCUSSION 162 
Our method provided useful insights into the prevalence of LTBI in Australia; a low-incidence setting with 163 
high levels of migration. Both the prevalence and total number of people with LTBI in Australia rose from 164 
2006 to 2016, with the highest proportions seen in major metropolitan areas. The increasing prevalence of 165 
LTBI can be attributed to increasing numbers of overseas-born residents from countries with a high burden 166 
of TB such as India, China and the Philippines. New arrivals were predominantly young adults and families, 167 
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such that an increasing proportion of those estimated to have LTBI during the study period were under 35 168 
years of age. During this time, we found that around 15% of migrants to Australia had LTBI. However, due to 169 
high levels of migration from high-burden countries since the 1980s, the majority of those estimated to have 170 
LTBI in Australia in 2016 were over 35 years of age.   171 
Our study highlighted that despite the increasing prevalence of LTBI in Australia, the prevalence is low (5.1% 172 
in 2016) and far lower than the estimated global burden of 23% in 2014.7 Moreover, the proportion of 173 
residents estimated to have LTBI in the overseas-born population appeared to fall over time, due to the 174 
declining incidence of TB in the countries where most overseas-born residents were born (for example, India, 175 
and China).19 How the prevalence of LTBI in Australia, and other similar low-incidence settings, change in the 176 
future will be influenced by rates of migration, age at migration, source countries, and how TB incidence in 177 
those source countries changes over time, in addition to the implementation and effectiveness of any 178 
additional TB control strategies locally. 179 
Looking to the future, the addition of LTBI screening and treatment could be considered for migrant groups 180 
in Australia, as is done in several other low-incidence countries.22 LTBI treatment is commonly limited to 181 
those aged under 35 years because the frequency of adverse effects increases with age,23 24 although recent 182 
research has shown that shorter LTBI treatment regimens containing rifampicin have a significantly lower 183 
risk of hepatotoxicity, so recommendations for testing older age groups may expand into the future.25 Our 184 
approach is able to quantify LTBI burden in sub-populations from low-burden countries, ensuring improved 185 
estimates of the pre-test probability of LTBI essential for predicting the efficiency of any proposed screening 186 
program. In addition, understanding LTBI distribution is helpful even where preventive therapy would not be 187 
indicated, and allows alternative interventions (such as community and healthcare worker education about 188 
TB disease) to be optimised. Migrants arriving from  high-burden settings from 2007 to 2016 made up over 189 
30% of all those with LTBI in Australia in 2016, and because recently arriving migrants are at higher risk of 190 
reactivating than those that have settled in Australia for longer 26 screening and treating this group may be 191 
beneficial. Quantifying this benefit will be a focus of future work,  which will incorporate estimation of TB 192 
reactivation rates among sub-populations with LTBI. Given the significant uncertainty around rates of LTBI 193 
reactivation27 this work will be beneficial in predicting the benefit of screening and treatment strategies in 194 
our setting.   195 
In low incidence settings, where national TST prevalence surveys have long been abandoned and the 196 
majority of cases occur among overseas-born residents, indirect LTBI estimates based on modelled annual 197 
risks of infection in countries of birth combined with migration data are a natural approach. Our analysis 198 
incorporates both TB incidence in countries-of-birth and age, both of which have been shown to be 199 
independently associated with the prevalence of LTBI among migrants in the international literature.6 28 29 200 
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Limitations of our approach include that applying a constant ARTI for all residents of a particular country in a 201 
particular year obscures individual variation in risk within populations due to a range of risk factors, such as 202 
immunological status.30  203 
Migrants who move from a high TB-burden setting to a low-incidence setting may do so for many different 204 
reasons and may not be representative (demographically or socioeconomically) of individuals of the same 205 
age in their country of origin,31 which may influence their risk of having been infected. Most LTBI prevalence 206 
studies, including those in Australia,32-34 exclusively consider refugee populations; which are often screened 207 
due to a  perception of higher risk.35 Previously published LTBI prevalence in these populations do exceed 208 
our estimates (data not shown),32-34 however, humanitarian entrants made up only 2-3% of all migrants to 209 
Australia from 2006-2016, and we consider this unlikely to substantially impact our estimates presented 210 
here.36 Further, we note that several international studies in migrant cohorts have resulted in similar 211 
estimates to those using our method. LTBI prevalence estimates in the entire US migrant population were 212 
provided by Shea et al. 2014 using results from the 1999-2000 National Health and Nutrition Examination 213 
Survey, and they reported that 18.7% of overseas-born residents had LTBI. In comparison, our method leads 214 
to an estimated prevalence of 18.0% in overseas-born Australians in 2006. A separate UK study among all 215 
migrants attending three UK medical centres (2008-2010) found 144/740 (20%) born in the Indian 216 
subcontinent (≤35 years) were IGRA positive,6 and on equivalent subsets from the Australian migration data 217 
in 2006 (by country of birth, year of arrival and age), we estimated 20.9% to have LTBI. Overall, then, our 218 
estimates appear concordant with existing data from testing in migrant populations. 219 
Some uncertainty must also be acknowledged due to the small amount of missing census data. Despite this, 220 
census data remains a good source of comprehensive data, and post-enumeration survey data suggested 221 
that the countries of birth of census non-respondents did not differ greatly from the census respondents,9 222 
meaning that although we have probably slightly underestimated the numbers with LTBI, the proportions 223 
presented should be less affected.   224 
Our method also made the assumption that, once infected, individuals remained infected for life, and so 225 
provides information about the risk of an individual having ever been infected. No allowance was made for 226 
the possibility that individuals may clear LTBI over time since infection, for which there is evidence.37 38 227 
Furthermore, in some settings LTBI screening and treatment may already be systematically provided to 228 
certain migrant groups and LTBI estimates may need to account for this. This is not the case in Australia, 229 
where overseas visa applicants identified has having a CXR revealing old, inactive TB may be offered LTBI 230 
screening and treatment as part of their health follow-up,39 however the impact of these practices on overall 231 
LTBI prevalence is likely to be small, due to the small number of migrants referred to the program.40  232 
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Our method combines global TB infection estimates with migration data to provide useful insights into the 233 
prevalence of latent TB in our low-incidence setting. The method could be easily repeated in any setting with 234 
reliable census data. Resulting quantitative estimates can assist in developing rational strategies for LTBI 235 
screening, which allow for opportunities to promote the long-term health of overseas-born residents and 236 
contribute towards the ultimate goal of global TB elimination. 237 
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Table 1 Estimated LTBI among Australian residents in 2016, with country-specific results from the ten countries of birth  contributing the greatest numbers with LTBI. 348 
Country of birth 
Percentage 
of 
Australian 
population 
(%) 
Median 
number, in 
thousands, 
estimated to 
have LTBI in 
Australia  
(IQR) 
Median 
age of 
resident 
with LTBI 
(years) 
Median years 
since arrival 
of those 
estimated to 
have LTBI 
Median 
percentage of 
all LTBI in 
Australia 
(%) 
Median percentage with LTBI by age group (IQR) 
0-14  
years 
15-34  
years 
35-64  
years 
≥ 65  
years 
All 
China 2.3 113 53 12 11.8 1.5 9.1 29.2 65.6 21.3 
 (89-140)    (1.4-1.6) (8.5-9.8) (22.3-38.4) (43.2-85.8) (16.8-26.6) 
India 2.1 115 36 8 12.1 2.9 22.9 31.5 45.9 26.0 
 (108-124)    (2.7-3.1) (21.6-24.3) (29.3-34.5) (38.2-54.9) (24.4-28.0) 
Philippines 1.1 101 47 12 10.6 6.8 28.1 55.3 80.2 44.7 
 (85-117)    (6.3-7.3) (26.5-30.0) (45.8-66.1) (57.4-96.0) (37.9-51.8) 
Vietnam 1.0 96 55 27 10.0 3.3 18.9 49.9 91.0 45.5 
 (61-125)    (3.0-3.6) (17.0-21.4) (29.8-70.0) (57.8-99.9) (29.1-59.5) 
South Africa 0.7 37 45 9 3.8 8.2 16.8 27.4 25.8 22.9 
 (30-52)    (7.6-9.0) (15.9-18.3) (21.5-39.1) (16.1-56.9) (18.6-32.4) 
Indonesia 0.3 32 41 13 3.3 7.9 34.4 53.1 67.5 44.6 
 (30-33)    (7.4-8.4) (33.1-35.6) (50.9-55.5) (56.4-79.7) (42.7-46.6) 
Cambodia 0.2 24 49 25 2.6 11.5 50.0 85.6 100.0 76.0 
 (20-26)    (10.8-12.2) (46.2-54.6) (66.0-93.3) (91.4-100.0) (62.6-82.0) 
South Korea  0.5 25 49 14 2.6 1.4 9.1 39.6 92.6 26.7 
 (23-27)    (1.3-1.6) (8.5-9.9) (36.0-43.2) (84.9-97.8) (24.5-28.5) 
Pakistan 0.3 17 35 5 1.8 4.1 24.2 41.5 68.7 27.9 
 (15-18)    (3.8-4.4) (23.0-25.6) (36.0-48.5) (54.3-79.6) (25.4-30.9) 
Myanmar 0.2 16 45 8 1.7 9.4 34.3 60.4 87.3 51.1 
 (13-18)    (8.5-10.2) (32.0-36.6) (49.4-75.7) (61.2-98.4) (42.6-59.1) 
Other countries 19.6 413 56 25 39.8 0.9 5.4 10.4 16.8 10.4 
 (378-456)    (0.9-1.0) (5.3-5.6) (9.7-11.2) (14.6-20.1) (9.5-11.4) 
All overseas-born 28.3 998 49 15 93.2 2.1 11.3 20.1 22.9 17.1 
 (943-1058)    (2.0-2.1) (11.1-11.6) (18.7-21.3) (20.6-25.8) (16.2-18.1) 
Australian-born 71.7 65 54 - 6.8 0.1 0.3 0.6 0.9 0.4 
 (48-112)    (0.1-0.1) (0.2-0.3) (0.4-0.9) (0.5-2.3) (0.3-0.7) 
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 349 
 350 
Figure 1 Number and percentage of Australians estimated to have LTBI by census year. Vertical lines represent data points that are 351 
no more than 1.5 times the interquartile range from the box. 352 
 353 
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 354 
Figure 2 Estimated number and percentage estimated to have LTBI by age group and census year. Vertical lines represent data 355 
points that are no more than 1.5 times the interquartile range from the box. 356 
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 357 
Figure 3 Number arriving by year of Australian residents in 2016 who were born in countries with a high burden of TB (as defined 358 
by the WHO 2017 Global TB Report19). Birth countries with fewer than 10,000 residents excluded. 359 
 360 
 361 
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   362 
Figure 4 Estimated number of overseas-born residents in Australia for the four most common countries of birth, by age and LTBI 363 
status, at time of migration and as at the 2016 census. 364 
  365 
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Appendices 366 
The probabilities of infection in the Australian-born (pa) and in the overseas-born (po) are given by: 367 
𝑝𝑎 = 1 −  𝑒
−𝐻𝑎  368 
𝑝𝑜 = 1 −  𝑒
−𝐻𝑜  369 
𝐻𝑎 =  
1
2⁄ 𝐹𝑂𝐼𝑏𝑎 + ∑ 𝐹𝑂𝐼𝑖𝑎
𝑓
𝑖=𝑏+1
 370 
𝐻𝑜 =  
1
2⁄ 𝐹𝑂𝐼𝑏𝑠 + ∑ 𝐹𝑂𝐼𝑖𝑠
𝑚−1
𝑖=𝑏+1
+ 1 2⁄ 𝐹𝑂𝐼𝑚𝑠 +
1
2⁄ 𝐹𝑂𝐼𝑚𝑎 + ∑ 𝐹𝑂𝐼𝑖𝑎
𝑓
𝑖=𝑚+1
 371 
Where FOI indicates the force of infection that an Australian-born (a) or overseas-born (o) person was 372 
exposed to in a specific year and country, and H indicates the cumulative force of infection. The subscripts a, 373 
b, m, s and f refer to Australia, birth year, migration year, source country and final year of calculation 374 
respectively, and are applied to forces of infection in specific years and countries. 375 
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a)  376 
 377 
b)  378 
Figure S1 Estimated percentage of residents with LTBI in Australia over time by a) region of Australia and b) 379 
local government area in Greater Melbourne.  380 
